2017 Q1 Form 10-K Financial Statement
#000156459017005798 Filed on March 31, 2017
Income Statement
| Concept | 2017 Q1 | 2016 Q4 | 2016 Q3 |
|---|---|---|---|
| Revenue | $1.192M | $766.0K | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $200.0K | $190.0K | $10.00K |
| YoY Change | -93.59% | -93.38% | -99.66% |
| % of Gross Profit | |||
| Research & Development | $4.651M | $3.184M | $7.089M |
| YoY Change | -52.4% | -55.51% | -0.04% |
| % of Gross Profit | |||
| Depreciation & Amortization | $66.00K | ||
| YoY Change | 8.2% | ||
| % of Gross Profit | |||
| Operating Expenses | $6.738M | $5.274M | $5.963K |
| YoY Change | -47.72% | -47.41% | -99.94% |
| Operating Profit | -$5.963K | ||
| YoY Change | |||
| Interest Expense | $797.0K | $457.0K | $521.0K |
| YoY Change | 20.21% | -33.67% | 2.36% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$793.0K | -$437.0K | -$496.0K |
| YoY Change | 21.25% | -36.39% | -1.78% |
| Pretax Income | -$240.0K | -$200.0K | -$20.00K |
| YoY Change | -98.23% | -98.13% | -99.81% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$6.339M | -$4.945M | -$9.959M |
| YoY Change | -53.19% | -53.85% | -5.61% |
| Net Earnings / Revenue | -531.8% | -645.56% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$263.7K | -$227.3K | -$24.39K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 29.02M | 27.44M | 820.0K |
| Diluted Shares Outstanding | 830.5K |
Balance Sheet
| Concept | 2017 Q1 | 2016 Q4 | 2016 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $12.03M | $40.00K | $38.06M |
| YoY Change | -80.12% | -99.95% | -50.97% |
| Cash & Equivalents | $94.02K | $44.61K | $14.07K |
| Short-Term Investments | |||
| Other Short-Term Assets | $2.450M | ||
| YoY Change | |||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $1.139M | $823.0K | $1.150M |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $15.61M | $36.79M | $39.20M |
| YoY Change | -74.86% | -52.41% | -50.47% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $114.0K | $668.0K | $700.0K |
| YoY Change | -83.48% | 15.97% | 100.0% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $230.0K | $12.68K | $230.0K |
| YoY Change | 0.0% | -96.35% | -62.3% |
| Total Long-Term Assets | $344.0K | $898.0K | $930.0K |
| YoY Change | -62.61% | -2.71% | -4.12% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $15.61M | $36.79M | $39.20M |
| Total Long-Term Assets | $344.0K | $898.0K | $930.0K |
| Total Assets | $15.95M | $37.69M | $40.13M |
| YoY Change | -74.69% | -51.82% | -49.91% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $644.0K | $1.446M | $1.780M |
| YoY Change | -70.59% | -35.04% | -17.59% |
| Accrued Expenses | $3.538M | $4.611M | $5.920M |
| YoY Change | -36.37% | -28.61% | 34.55% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $700.0K | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $8.190M | |
| YoY Change | -100.0% | 103.23% | |
| Total Short-Term Liabilities | $6.682M | $755.2K | $15.89M |
| YoY Change | -57.11% | -95.38% | 49.76% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $6.550M |
| YoY Change | -100.0% | -100.0% | -37.8% |
| Other Long-Term Liabilities | $162.0K | $1.206M | $1.080M |
| YoY Change | -78.96% | 154.97% | 217.65% |
| Total Long-Term Liabilities | $1.530M | $7.638M | $7.630M |
| YoY Change | -86.65% | -41.89% | -29.81% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $6.682M | $755.2K | $15.89M |
| Total Long-Term Liabilities | $1.530M | $7.638M | $7.630M |
| Total Liabilities | $8.212M | $755.2K | $23.51M |
| YoY Change | -69.63% | -97.44% | 9.5% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$207.0M | -$727.8K | |
| YoY Change | -99.55% | ||
| Common Stock | $214.8M | $17.21K | |
| YoY Change | -99.99% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $7.741M | -$710.6K | $16.62M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $15.95M | $44.61K | $40.13M |
| YoY Change | -74.69% | -99.94% | -49.91% |
Cashflow Statement
| Concept | 2017 Q1 | 2016 Q4 | 2016 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$6.339M | -$4.945M | -$9.959M |
| YoY Change | -53.19% | -53.85% | -5.61% |
| Depreciation, Depletion And Amortization | $66.00K | ||
| YoY Change | 8.2% | ||
| Cash From Operating Activities | -$50.00K | -$160.0K | $24.29M |
| YoY Change | -99.62% | -98.05% | -404.77% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | |||
| YoY Change | |||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | ||
| YoY Change | -100.0% | ||
| Cash From Investing Activities | $0.00 | ||
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $62.00K | ||
| YoY Change | 51.22% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 100.0K | 200.0K | 3.860M |
| YoY Change | -105.29% | -96.97% | 2473.33% |
| NET CHANGE | |||
| Cash From Operating Activities | -50.00K | -160.0K | 24.29M |
| Cash From Investing Activities | 0.000 | ||
| Cash From Financing Activities | 100.0K | 200.0K | 3.860M |
| Net Change In Cash | 50.00K | 40.00K | 28.15M |
| YoY Change | -100.32% | -102.33% | -458.6% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$50.00K | -$160.0K | $24.29M |
| Capital Expenditures | |||
| Free Cash Flow | |||
| YoY Change |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
77302000 | |
| CY2015Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
347000 | |
| CY2016 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
27565000 | |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
37920000 | |
| CY2016 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2016 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2016 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2016 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2017Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
29021455 | |
| CY2016Q2 | dei |
Entity Public Float
EntityPublicFloat
|
47569338 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
75908000 | |
| CY2015Q4 | ceru |
Accounts Receivable Prepaid Expense And Other Current Assets
AccountsReceivablePrepaidExpenseAndOtherCurrentAssets
|
1394000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
576000 | |
| CY2015Q4 | us-gaap |
Assets
Assets
|
78225000 | |
| CY2015Q4 | us-gaap |
Loans Payable Current
LoansPayableCurrent
|
7652000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
2500000 | |
| CY2015Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
12672000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1993000 | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
213788000 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
210115000 | |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10355000 | |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-94299000 | |
| CY2014 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
140000 | |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
885000 | |
| CY2014 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
81526000 | |
| CY2014 | ceru |
Conversion Of Convertible Notes
ConversionOfConvertibleNotes
|
20129000 | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
45325000 | |
| CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1628000 | |
| CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2375000 | |
| CY2016 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
78000 | |
| CY2016 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
54000 | |
| CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2755000 | |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
187000 | |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
885000 | |
| CY2014 | us-gaap |
Straight Line Rent Adjustments
StraightLineRentAdjustments
|
29000 | |
| CY2014 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
126000 | |
| CY2014 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
28000 | |
| CY2014 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
215000 | |
| CY2016 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
5000000 | |
| CY2016 | us-gaap |
Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
|
507000 | |
| CY2016 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
446000 | |
| CY2015 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
-342000 | |
| CY2014 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
695000 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-603000 | |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
795000 | |
| CY2016 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
7922000 | |
| CY2015 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
3321000 | |
| CY2015 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
359000 | |
| CY2014 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
222000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
57133000 | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
64932000 | |
| CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
24734000 | |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
45686000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
51174000 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5488000 | |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
341000 | |
| CY2016 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1268000 | |
| CY2015 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
3283000 | |
| CY2014 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1419000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-33536000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-31915000 | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-19061000 | |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
535000 | |
| CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
277000 | |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
225000 | |
| CY2015 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
23000 | |
| CY2014 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
40000 | |
| CY2016 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-117000 | |
| CY2015 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
230000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-418000 | |
| CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
918000 | |
| CY2015 | ceru |
Proceeds From Issuance Public Offering Net
ProceedsFromIssuancePublicOfferingNet
|
37185000 | |
| CY2014 | ceru |
Proceeds From Issuance Public Offering Net
ProceedsFromIssuancePublicOfferingNet
|
59862000 | |
| CY2015 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
21000000 | |
| CY2014 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
8500000 | |
| CY2015 | ceru |
Property And Equipment In Accounts Payable
PropertyAndEquipmentInAccountsPayable
|
177000 | |
| CY2014 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
81526000 | |
| CY2014 | us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
20129000 | |
| CY2014 | ceru |
Reclassification Of Warrants To Additional Paid In Capital
ReclassificationOfWarrantsToAdditionalPaidInCapital
|
424000 | |
| CY2015 | ceru |
Noncash Warrants Issued With Term Loan Facility
NoncashWarrantsIssuedWithTermLoanFacility
|
824000 | |
| CY2014 | us-gaap |
Interest Paid Net
InterestPaidNet
|
400000 | |
| CY2016 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:bold;">1.</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NATURE OF BUSINESS AND OPERATIONS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Nature of Business<font style="font-weight:normal;"> — Cerulean Pharma Inc. (the “Company”) was incorporated on November 28, 2005, as a Delaware corporation and is located in Waltham, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and other diseases. In 2013, the Company formed a wholly owned subsidiary, Cerulean Pharma Australia Pty Ltd as an Australian-based proprietary limited company to perform clinical activities in Australia. </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's operations have consisted primarily of raising capital, product research and development, and initial market development.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not generated any revenue related to its primary business purpose to date and is subject to a number of risks common to other development stage life science companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products, and the need to obtain adequate additional financing to fund the development of product candidates. The Company is also subject to a number of risks similar to other companies in the industry, including rapid technological change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key individuals.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an accumulated deficit of $200.7 million at December 31, 2016. The Company has financed its operations primarily through private placements of its preferred stock, proceeds from borrowings, an initial public offering completed in 2014 and a follow-on offering completed in 2015. In October 2016 the Company entered into a collaboration with Novartis Institutes for BioMedical Research, Inc. (“Novartis”) to develop nanoparticle-drug conjugates combining the Company’s proprietary Dynamic Tumor Targeting technology with Novartis’ proprietary compounds. Under this collaboration the Company received important funding to support its research program. The Company has not completed development of any product candidate and has devoted substantially all of its financial resources and efforts to research and development, including preclinical and clinical development. Accordingly, the Company will continue to depend on its ability to raise capital through equity and debt issuances and/or through strategic partnerships. The Company expects to continue to incur significant expenses and increasing operating losses for at least several years.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2016, the Company had cash and cash equivalents of $35.0 million. The Company has no other sources of significant liquidity in place as of December 31, 2016. The Company expects that its existing cash and cash equivalents will fund its operations into the second half of 2017 based on the Company’s 2017 operating plan. The Company has undertaken a strategic review of potential financing alternatives such as the sale of the company, a merger, a business combination, a strategic investment into the company, or a sale, license or disposition of assets of the Company. If the Company is unable to obtain additional funding on a timely basis, it may be required to curtail or terminate research and development activities under its collaboration agreement with Novartis, or to scale back, suspend or terminate its business operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As more fully discussed in Note 17 Subsequent Events, pursuant to management’s plans, in March 2017 the Company entered into a series of transactions including the payoff of its note payable to Hercules Capital for $12.4 million. The Company sold and assigned all of its right, title and interest in and to its clinical product candidates CRLX101 and CRLX301 for proceeds of $1.5 million. The Company also <font style="Background-color:#FFFFFF;">agreed to sell and assign to Novartis all of its right, title and interest in and to the patent rights, know-how and third-party license agreements relating to </font>its Dynamic Tumor Targeting Platform technology for proceeds of $6.0 million, whereby the proceeds from this asset sale are to be received upon closing of the transaction. The Company also entered into a Stock Purchase Agreement with Daré Biosciences, Inc., which if approved by the shareholders, will be consummated by an exchange of common stock shares and no cash consideration paid or received.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With exception of the payoff of the note payable and the sale of the clinical product candidates, these transactions are subject to certain closing conditions. There can be no assurances that these transactions will be consummated prior to the exhaustion of the Company’s cash and cash equivalent resources, if at all.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing matters give rise to substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"> </p></div> | |
| CY2016 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-weight:normal;"> — </font><font style="color:#000000;font-weight:normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</font></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company's management evaluates its estimates, including estimates related to clinical trial accruals, stock-based compensation expense, and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p></div> | |
| CY2016 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentrations of Credit Risk<font style="font-weight:normal;"> — Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents are held at one financial institution that management believes to be of high-credit quality. Deposits with this financial institution may exceed the amount of insurance provided on such deposits; however these deposits may be redeemed upon demand and, therefore, bear minimal risk. </font></p></div> | |
| CY2016Q4 | ceru |
Accrued Indemnification Provisions
AccruedIndemnificationProvisions
|
0 | |
| CY2016Q4 | ceru |
Claims Related To Indemnification Obligations
ClaimsRelatedToIndemnificationObligations
|
0 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.39 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.86 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
4.12 | |
| CY2016 | us-gaap |
Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Guarantees and Indemnification<font style="font-weight:normal;"> — As permitted under Delaware law, the Company indemnifies its officers and directors employees for certain events or occurrences while the officer or director is, or was serving at the Company’s request in such a capacity. The term of the indemnification is for the officer’s or director’s lifetime. During the year ended December 31, 2016, the Company </font><font style="font-weight:normal;">did not experience any losses related to these indemnification obligations. The Company does not expect significant claims related to these indemnification obligations, and consequently, has concluded the fair value of these obligations is not material. Accordingly, as of December 31, 2016 no amounts have been accrued related to such indemnification provisions.</font></p></div> | |
| CY2016 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2005-11-28 | |
| CY2016 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
230000 | |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
347000 | |
| CY2015 | ceru |
Lease Expiration Period Month And Year
LeaseExpirationPeriodMonthAndYear
|
2016-02 | |
| CY2016 | ceru |
Lease Expiration Period Month And Year
LeaseExpirationPeriodMonthAndYear
|
2021-02 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
700000 | |
| CY2015Q4 | us-gaap |
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
|
600000 | |
| CY2016 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
|
0 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1597570 | |
| CY2016 | ceru |
Loss On Indemnification Obligations
LossOnIndemnificationObligations
|
0 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
1032208 | |
| CY2016 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-39305000 | |
| CY2015 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-39594000 | |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-23342000 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.31 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
5.41 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
4.33 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y10M24D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y4M24D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y8M12D | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y4M24D | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2060000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1722000 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1392000 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1146000 | |
| CY2016Q4 | ceru |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
2648000 | |
| CY2015Q4 | ceru |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
2631000 | |
| CY2016Q4 | ceru |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
226000 | |
| CY2016Q4 | us-gaap |
Loans Payable
LoansPayable
|
12821000 | |
| CY2016Q4 | ceru |
Unamortized Deferred Financing Costs
UnamortizedDeferredFinancingCosts
|
100000 | |
| CY2016Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
200000 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4020288 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1634944 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
3900976 | |
| CY2016Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4385852 | |
| CY2015Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4296440 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3454926 | |
| CY2015Q4 | ceru |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
945000 | |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1080000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1864000 | |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
82000 | |
| CY2015Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
136000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
575000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
883000 | |
| CY2016Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
8533000 | |
| CY2016Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
4544000 | |
| CY2016Q4 | ceru |
Debt Instrument Unamortized Discount And Deferred Financing Cost
DebtInstrumentUnamortizedDiscountAndDeferredFinancingCost
|
256000 | |
| CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2755000 | |
| CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2375000 | |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
885000 | |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0120 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0145 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0171 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0232 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0202 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0200 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.61 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.51 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.54 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.68 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.63 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.60 | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
35000000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
75300000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
42211 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
35797 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2486 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2066 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
4453 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
3977 | |
| CY2016Q4 | ceru |
Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
|
24923 | |
| CY2015Q4 | ceru |
Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
|
17715 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1878 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
903 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
75951 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
60458 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
75951 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
60458 | |
| CY2016Q4 | us-gaap |
Revenues
Revenues
|
766000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2016 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
15500000 | |
| CY2015 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
15600000 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.340 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.340 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.050 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.050 | |
| CY2016 | ceru |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.006 | |
| CY2015 | ceru |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.005 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.011 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.009 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.005 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.007 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.002 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.004 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.392 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.391 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2016 | ceru |
Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
|
2036 | |
| CY2015 | ceru |
Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
|
2035 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit
DeferredRentCredit
|
153000 | |
| CY2016 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
728000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
690000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
738000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
786000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
830000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
140000 | |
| CY2016Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
3184000 | |
| CY2014Q2 | us-gaap |
Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
|
30000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9770000 | |
| CY2016Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7522000 | |
| CY2016Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7089000 | |
| CY2016Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3184000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3118000 | |
| CY2016Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2773000 | |
| CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2374000 | |
| CY2016Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2090000 | |
| CY2016Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
12888000 | |
| CY2016Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
10295000 | |
| CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
9463000 | |
| CY2016Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
5274000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
16000 | |
| CY2016Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
25000 | |
| CY2016Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
25000 | |
| CY2016Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
20000 | |
| CY2016Q1 | us-gaap |
Interest Expense
InterestExpense
|
670000 | |
| CY2016Q2 | us-gaap |
Interest Expense
InterestExpense
|
589000 | |
| CY2016Q3 | us-gaap |
Interest Expense
InterestExpense
|
521000 | |
| CY2016Q4 | us-gaap |
Interest Expense
InterestExpense
|
457000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-654000 | |
| CY2016Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-564000 | |
| CY2016Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-496000 | |
| CY2016Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-437000 | |
| CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7092000 | |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
721000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-13542000 | |
| CY2016Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10859000 | |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9959000 | |
| CY2016Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4945000 | |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.49 | |
| CY2016Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.40 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | |
| CY2016Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.17 | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27362643 | |
| CY2016Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27363965 | |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27383376 | |
| CY2016Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28724083 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5021000 | |
| CY2015Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6678000 | |
| CY2015Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7157000 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2681000 | |
| CY2015Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2717000 | |
| CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2954000 | |
| CY2015Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2872000 | |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
7702000 | |
| CY2015Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
9395000 | |
| CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
10046000 | |
| CY2015Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
10029000 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3000 | |
| CY2015Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1000 | |
| CY2015Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4000 | |
| CY2015Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | |
| CY2015Q2 | us-gaap |
Interest Expense
InterestExpense
|
513000 | |
| CY2015Q3 | us-gaap |
Interest Expense
InterestExpense
|
509000 | |
| CY2015Q4 | us-gaap |
Interest Expense
InterestExpense
|
689000 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-718000 | |
| CY2015Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-512000 | |
| CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-505000 | |
| CY2015Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-687000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8420000 | |
| CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9907000 | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10551000 | |
| CY2015Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10716000 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.41 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.39 | |
| CY2015Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.39 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20350557 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26690673 | |
| CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27307103 | |
| CY2015Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27346780 |
